StartUPDATES: New developments from healthcare startups

Vector illustration - Startup

Vector illustration - Startup

Carrum Health launched CarrumComplete™, its new complete surgical care platform to give employers the industry’s first single stop for surgical care. The new offering is powered by CarrumLOCAL™, which matches employer populations with the highest quality surgeons from both the Carrum Health Centers of Excellence (COE) Network and, where a COE may not be generally available, local options within the employer’s health plan.

Carrum Health’s new platform manages the entire surgical care journey for the member, from care guidance to scheduling and coordination, all the way through the surgical procedure – or helps them avoid surgery altogether if more conservative options are more appropriate. For employers, this approach eliminates the need for multiple care point solutions and leads to savings of up to 45% per surgical procedure, with additional savings from avoided surgeries.

“Quality is the most critical element of healthcare and leads to lower costs for employers. COE programs are a great tactic for employers to reduce the high procedure spend, while improving outcomes and experience for their employees,” said Drew Hodgson, national practice leader of Health Care Delivery at Willis Towers Watson. “Carrum Health’s new platform, built upon the rigorous approach to evaluating quality of care, addresses the major access challenge that employers face in adopting COE solutions.”

ThoroughCare, Inc., an integrated care coordination software platform that enables healthcare providers to effectively deliver value-based care, has received a $3 million investment from Cypress Growth Capital. The investment of funds will be used to accelerate growth through platform technology enhancements, expand business development efforts into new markets, and nurture customer success initiatives.

ThoroughCare, which recently launched ThoroughCare Analytics, enables physicians and caregivers to streamline patient engagement, enable integrated, coordinated care, and simplify value-based reimbursement programs. It has helped physician groups, clinics, and health centers overcome healthcare challenges through intuitive software solutions for streamlined patient care.

To learn more, click here.

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, has closed a $37 million Series A financing led by Kineticos Ventures.

Proceeds from the Series A financing will be used to advance Inceptor Bio’s CAR-T lead program to a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms. Additionally, proceeds will support completion of Inceptor Bio’s Advanced Manufacturing Platform (AMP+) facility, a 29,000 square foot, state-of-the-art cell and gene therapy GMP manufacturing site located in Gainesville, Florida.

Inceptor Bio’s CAR-T, CAR-M, and CAR-NK platforms are at the center of a diversified portfolio of cell therapies focused on novel mechanisms that enhance cell performance in the tumor microenvironment. Novel technologies include a co-stimulatory domain M83, proprietary TMax manufacturing process, the K62 platform, which increases the phagocytic capabilities of macrophages and supports a M1 anti-tumor phenotype, and a differentiated iPSC technology.

To learn more, click here.

Gener8or recently selected startups for its latest cohort. They include:

  • Mother of Fact‘s on-demand HIPAA secure mobile app supports any mom as they navigate all baby feeding needs, serving the fragmented $14 billion market for pregnancy and baby care.
  • Q-rounds™ provides an in-hospital digital health solution that sends real-time updates for patients, their families, and the careteam on when to expect their doctor to arrive for inpatient rounds.
  • OmniVis developed a detection device to support international aid organizations and practicing physicians in  diagnosing infectious diseases.
  • SingleTimeMicroneedles created a painless, removable, transdermal microneedle patch that can deliver vaccines in the comfort of a person’s home.
  • Tiumed’s high-performance, easy to adopt surgical platform targets benign prostatic hyperplasia (BPH) surgery, an enlarged prostate treatment 1 in 4 men will require in their lifetime.

To learn more, click here.

Picture: akindo, Getty Images

Source link